Compare INDP & GTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDP | GTN |
|---|---|---|
| Founded | 2000 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.4M | 432.5M |
| IPO Year | 2021 | 1996 |
| Metric | INDP | GTN |
|---|---|---|
| Price | $3.07 | $4.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 451.9K | ★ 831.8K |
| Earning Date | 11-11-2026 | 11-06-2026 |
| Dividend Yield | N/A | ★ 6.93% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,095,000,000.00 |
| Revenue This Year | N/A | $17.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $3.55 |
| 52 Week High | $5.96 | $6.44 |
| Indicator | INDP | GTN |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 53.85 |
| Support Level | $2.05 | $4.47 |
| Resistance Level | $3.75 | $4.70 |
| Average True Range (ATR) | 0.33 | 0.19 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 78.48 | 64.66 |
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios. The company's segments include Broadcasting and Production Companies. The majority of revenue is derived from broadcast and digital advertising and from retransmission consent fees.